84年鼠女哪年财运最旺,857comvvv色九欧美激情|85PO_87国产精品欲av国产av资源

[1]吉富濤,閆露露,馮新越,等.基于中醫(yī)傳承輔助平臺(tái)探討國(guó)家專利中藥復(fù)方治療骨髓炎的組方規(guī)律[J].中醫(yī)正骨,2023,35(08):51-56,60.
　JI Futao,YAN Lulu,FENG Xinyue,et al.A data mining-based analysis of clinical medication rules of national patent Chinese herbal compound prescriptions against osteomyelitis based on traditional Chinese medicine inheritance support system[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2023,35(08):51-56,60.
點(diǎn)擊復(fù)制

基于中醫(yī)傳承輔助平臺(tái)探討國(guó)家專利中藥復(fù)方治療骨髓炎的組方規(guī)律()
分享到：

《中醫(yī)正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第35卷
期數(shù):
2023年08期
頁碼:
51-56,60
欄目:
數(shù)據(jù)庫研究
出版日期:
2023-08-20

文章信息/Info

Title:
A data mining-based analysis of clinical medication rules of national patent Chinese herbal compound prescriptions against osteomyelitis based on traditional Chinese medicine inheritance support system
作者:
吉富濤1; 閆露露1; 馮新越1; 黃鴻文1; 謝元洋1; 徐天利1; 陳葛1; 尹本敬2; 顧海潮2
1.云南中醫(yī)藥大學(xué)第一臨床醫(yī)學(xué)院,云南 昆明 650500; 2.云南省中醫(yī)醫(yī)院,云南 昆明 650021
Author(s):
JI Futao1; YAN Lulu1; FENG Xinyue1; HUANG Hongwen1; XIE Yuanyang1; XU Tianli1; CHEN Ge1; YIN Benjing2; GU Haichao2
1.The First Clinical Medical College of Yunnan University of Chinese Medicine,Kunming 650500,Yunnan,China 2.Yunnan Provincial Hospital of Traditional Chinese Medicine,Kunming 650021,Yunnan,China
關(guān)鍵詞:
骨髓炎;  復(fù)方(中藥);  專利;  數(shù)據(jù)挖掘;  方劑構(gòu)成;  組方原則;  聚類分析
Keywords:
osteomyelitis;  compounds(TCD);  patent;  data mining;  constitution of formula;  formula composing principles;  cluster analysis
摘要:
目的:探討國(guó)家專利中藥復(fù)方治療骨髓炎的組方規(guī)律。方法:通過計(jì)算機(jī)檢索國(guó)家知識(shí)產(chǎn)權(quán)局中國(guó)專利公布公告網(wǎng)(http://epub.cnipa.gov.cn/)中治療骨髓炎的中藥復(fù)方,按照納排標(biāo)準(zhǔn)篩選中藥復(fù)方,將篩選出的中藥復(fù)方的組方藥物及其劑量分別錄入Microsoft Office Excel 2010軟件和中醫(yī)傳承輔助平臺(tái)(V2.5),建立數(shù)據(jù)庫。采用Microsoft Office Excel 2010軟件統(tǒng)計(jì)每味藥物的出現(xiàn)頻次及藥物的性、味、歸經(jīng)分布情況,通過中醫(yī)傳承輔助平臺(tái)(V2.5)分析中藥復(fù)方的組方規(guī)律,并聚類生成新方。結(jié)果:共收集到106首中藥復(fù)方,涉及511味中藥,其中因穿山甲為國(guó)家一級(jí)保護(hù)動(dòng)物,故未對(duì)此藥做統(tǒng)計(jì)。510味中藥出現(xiàn)頻次≥3的有150味,其中排名前20位的中藥分別為金銀花、當(dāng)歸、黃芪、甘草、蒲公英、沒藥、骨碎補(bǔ)、丹參、乳香、紅花、紫花地丁、熟地黃、川牛膝、黃柏、黃連、黨參、茯苓、川芎、牡丹皮、三七。106首中藥復(fù)方的組方藥物中,藥性以寒性出現(xiàn)頻次最多,其次為溫性、平性; 藥味以苦味出現(xiàn)頻次最多,其次為甘味、辛味; 歸經(jīng)以肝經(jīng)出現(xiàn)頻次最多,其次為腎、脾、肺經(jīng); 出現(xiàn)頻次≥10的藥物組合有10個(gè),排在前3位的為金銀花-黃芪、金銀花-蒲公英、黃芪-當(dāng)歸; 核心藥物組合10個(gè),分別為金銀花-黃芪-黃連、射干-穿心蓮-北沙參、全蝎-肉桂-魚鰾、茯苓-天葵子-金櫻子、伸筋草-雞血藤-土牛膝、杜仲-續(xù)斷-骨碎補(bǔ)、板藍(lán)根-大黃-杏仁、三七-乳香-沒藥、知母-黃柏-蘇木、熟地黃-雞血藤-石膏。經(jīng)聚類分析得出新處方5首,分別為金銀花-黃芪-黃連-杜仲-續(xù)斷-骨碎補(bǔ)、射干-穿心蓮-北沙參-板藍(lán)根-大黃-杏仁、全蝎-肉桂-魚鰾-三七-乳香-沒藥、茯苓-天葵子-金櫻子-知母-黃柏-蘇木、伸筋草-雞血藤-土牛膝-熟地黃-石膏。結(jié)論:國(guó)家專利中藥復(fù)方治療骨髓炎,多用性偏寒,味偏苦,入肝、腎、脾、肺經(jīng)的中藥; 組方以清熱解毒、活血化瘀和消腫止痛藥為主,輔以補(bǔ)益氣血和托毒生肌藥; 核心組方和新方組合可為臨床遣方用藥和新藥開發(fā)提供參考,但其療效有待于進(jìn)一步研究。
Abstract:
Objective:To explore the clinical medication rules of national patent Chinese herbal compound(CHC)prescriptions in treatment of osteomyelitis.Methods:All CHC prescriptions for treatment of osteomyelitis were retrieved from the website(http://epub.cnipa.gov.cn/)of China Patent Announcement of China National Intellectual Property Administration through computer.The obtained patents were screened,and the CHC prescriptions involved in the patents were extracted according to the predefined inclusion and exclusion criteria.The Chinese herbs and their corresponding dosages in the screened CHC prescriptions were standardized and input into the Microsoft Office Excel 2010 software and the Traditional Chinese Medicine Inheritance Support System(TCMISS)software(V2.5)respectively to build the database.The statistics on occurrence frequency,property,flavour,meridian tropism of Chinese herbs in CHC prescriptions were conducted by using Microsoft Office Excel 2010 software,and their clinical medication rules were analyzed by using TCMISS software(V2.5),furthermore,the new prescriptions were predicted by cluster analysis.Results:One hundred and six CHC prescriptions were included in the final analysis,involving 511 Chinese herbs,among which Manis Squama was excluded from the statistics due to its original material came from the first-class national protected animal Manis pentadactyla Linnaeus.Among the 510 Chinese herbs,150 ones displayed a occurrence frequency of≥3,and the top 20 ones with high occurrence frequency included Lonicerae Japonicae Flos,Angelica sinensis,Astragalus propinquus,Glycyrrhizae Radix et Rhizoma(TCD),Taraxaci Herba,Myrrha,Drynariae Rhizoma,Salviae Miltiorrhizae Radix et Rhizoma(TCD),Olibanum(TCD),Carthami Flos(TCD),Violae Herba,Rehmanniae Radix Praeparata,Cyathula officinalis,Phellodendri Chinensis Cortex,Coptidis Rhizoma,Codonopsis Radix,Poria(TCD),Chuanxiong Rhizoma,Moutan Cortex and Notoginseng Radix et Rhizoma(TCD).The results of statistics on medicinal property,flavor and meridian tropism showed that,among the 106 CHC prescriptions,the most frequently used Chinese herbs were those with a cold property,followed by the ones with a warm property and a neutral property; the ones with bitter flavors were more preferred,followed by sweet and pungent flavors,and they mainly acted on the liver meridians,kidney meridians,spleen meridians and lung meridians.The results of analysis on prescription rules showed that,among the 106 CHC prescriptions,10 ones displayed a occurrence frequency of≥10,and the top 3 ones with high occurrence frequency included Lonicerae Japonicae Flos-Astragalus propinquus,Lonicerae Japonicae Flos-Taraxaci Herba and Astragalus propinquus-Angelica sinensis.The cluster analysis on all the included Chinese herbs generated 10 core herb combinations,namely Lonicerae Japonicae Flos-Astragalus propinquus-Coptidis Rhizoma,Belamcandae Rhizoma(TCD)-Andrographis Herba(TCD)-Glehniae Radix,Scorpio-Cinnamomi Cortex-Colla Pisces,Poria(TCD)-Semiaquilegiae Radix-Rosae Laevigatae Fructus,Lycopodii Herba-Spatholobi Caulis-Radix et Rhizoma Achyranthes,Eucommiae Cortex-Dipsaci Radix-Drynariae Rhizoma,Isatidis Radix-Rhei Radix et Rhizoma-Almond,Notoginseng Radix et Rhizoma(TCD)-Olibanum(TCD)-Myrrha,Anemarrhenae Rhizoma-Phellodendri Chinensis Cortex-Sappan Lignum and Rehmanniae Radix Praeparata-Spatholobi Caulis-Gypsum Fibrosum.Furthermore,5 new prescriptions were obtained by cluster analysis,namely Lonicerae Japonicae Flos-Astragalus propinquus-Coptidis Rhizoma-Eucommiae Cortex-Dipsaci Radix-Drynariae Rhizoma,Belamcandae Rhizoma(TCD)-Andrographis Herba(TCD)-Glehniae Radix-Isatidis Radix-Rhei Radix et Rhizoma-Almond,Scorpio-Cinnamomi Cortex-Colla Pisces-Notoginseng Radix et Rhizoma(TCD)-Olibanum(TCD)-Myrrha,Poria(TCD)-Semiaquilegiae Radix-Rosae Laevigatae Fructus-Anemarrhenae Rhizoma-Phellodendri Chinensis Cortex-Sappan Lignum and Lycopodii Herba-Spatholobi Caulis-Radix et Rhizoma Achyranthes-Rehmanniae Radix Praeparata-Gypsum Fibrosum.Conclusion:The Chinese herbs are often the ones presented with cold property and bitter flavor and mainly act on liver,kidney,spleen and lung meridians in CHC prescriptions from national patent database aimed at treating osteomyelitis,and the prescriptions are centred on clearing-heat and removing-toxicity,promoting blood circulation for removing blood stasis as well as detumescence for relieving pain herbs,supplemented by reinforcing Qi and Blood herbs as well as expressing toxins and promoting granulation herbs.The core herb combinations and new prescriptions can serve as references for clinical medication and new drug development,while their curative effects requires further research.

參考文獻(xiàn)/References:

[1] BURY D C,ROGERS T S,DICKMAN M M.Osteomyelitis:diagnosis and treatment[J].Am Fam Physician,2021,104(4):395-402.
[2] HOFSTEE M I,MUTHUKRISHNAN G,ATKINS G J,et al.Current concepts of osteomyelitis:from pathologic mechanisms to advanced research methods[J].Am J Pathol,2020,190(6):1151-1163.
[3] 文強(qiáng)強(qiáng),劉巖,蘇子龍,等.金黃色葡萄球菌骨髓炎發(fā)病機(jī)制的研究進(jìn)展[J].實(shí)用骨科雜志,2020,26(10):901-905.
[4] 董航,黃培鎮(zhèn),蔡群斌,等.“扶正消骨疽方”聯(lián)合局部病灶清除與抗生素負(fù)壓沖洗術(shù)治療慢性骨髓炎氣陰兩虛證36例臨床研究[J].江蘇中醫(yī)藥,2020,52(8):40-43.
[5] 俞華軍,馬茍平,張曉文,等.仙方活命飲加減結(jié)合手術(shù)治療慢性創(chuàng)傷性髕骨骨髓炎9例[J].浙江中醫(yī)雜志,2019,54(8):591.
[6] ROUX K M,COBB L H,SEITZ M A,et al.Innovations in osteomyelitis research:a review of animal models[J].Animal Model Exp Med,2021,4(1):59-70.
[7] 顧卓珺,顧維鳳,吳飛躍,等.醫(yī)院感染病原菌中藥與抗菌藥物聯(lián)合治療的研究[J].中華醫(yī)院感染學(xué)雜志,2015,25(10):2236-2238.
[8] 鄭世維,徐浩,李黔春,等.基于中醫(yī)理論探討化膿性骨髓炎的病因病機(jī)[J].中華中醫(yī)藥雜志,2017,32(1):80-83.
[9] 殷凡彪.烙法聯(lián)合仙方活命飲加減治療附骨疽的臨床效果[J].河南醫(yī)學(xué)研究,2020,29(16):3020-3022.
[10] 國(guó)家藥典委員會(huì).中華人民共和國(guó)藥典:一部[M].北京:中國(guó)醫(yī)藥科技出版社,2020.
[11] 顧勇,趙艷明,童培建,等.基于數(shù)據(jù)挖掘法探討中藥復(fù)方治療股骨頭壞死的組方規(guī)律[J].中醫(yī)正骨,2021,33(6):49-53.
[12] SCHMITT S K.Osteomyelitis[J].Infect Dis Clin North Am,2017,31(2):325-338.
[13] YANG J,YAO J L,WU Z Q,et al.Current opinions on the mechanism, classification,imaging diagnosis and treatment of post-traumatic osteomyelitis[J].Chin J Traumatol,2021,24(6):320-327.
[14] 竇涌泉,王衛(wèi)國(guó).王衛(wèi)國(guó)治療慢性骨髓炎經(jīng)驗(yàn)[J].湖南中醫(yī)雜志,2018,34(11):29-30.
[15] 譚偉欣,李國(guó)韶.透膿散治療成人慢性骨髓炎的臨床療效[J].內(nèi)蒙古中醫(yī)藥,2020,39(2):36-37.
[16] 喻杉,朱陽蓬勃,袁峰.基于快速康復(fù)理念“托毒補(bǔ)虛”中醫(yī)綜合方案對(duì)慢性骨髓炎術(shù)后恢復(fù)的療效觀察[J].四川中醫(yī),2019,37(12):141-144.
[17] PAN H,ZHOU H,MIAO S,et al.An integrated approach for global profiling of multi-type constituents:comprehensive chemical characterization of lonicerae japonicae flos as a case study[J].J Chromatogr A,2020,1613:460674.
[18] 曾安琪,華樺,陳朝榮,等.金銀花、山銀花抗炎藥理作用研究[J].中國(guó)中藥雜志,2020,45(16):3938-3944.
[19] 李偉霞,泥文娟,王曉艷,等.當(dāng)歸化學(xué)成分、藥理作用及其質(zhì)量標(biāo)志物(Q-marker)的預(yù)測(cè)分析[J].中華中醫(yī)藥學(xué)刊,2022,40(6):40-47.
[20] 曹顏冬.當(dāng)歸化學(xué)成分及藥理作用的分析[J].世界最新醫(yī)學(xué)信息文摘,2019,19(2):93.
[21] 胡妮娜,張曉娟.黃芪的化學(xué)成分及藥理作用研究進(jìn)展[J].中醫(yī)藥信息,2021,38(1):76-82.
[22] EL-SABER BATIHA G,MAGDY BESHBISHY A,EL-MLEEH A,et al.Traditional uses,bioactive chemical constituents, and pharmacological and toxicological activities of glycyrrhiza glabra L[J].Biomolecules,2020,10(3):352.
[23] 時(shí)永健,杜全紅,隋明軍,等.基于網(wǎng)絡(luò)藥理學(xué)探究清熱解毒與補(bǔ)氣養(yǎng)血中藥配伍對(duì)骨髓炎的分子作用機(jī)制[J].陜西中醫(yī),2021,42(6):797-801.
[24] 崔喜喜,韓宗昌,李記天,等.基于網(wǎng)絡(luò)藥理學(xué)和分子對(duì)接研究金銀花-黃芪藥對(duì)治療骨髓炎的分子機(jī)制[J].云南中醫(yī)學(xué)院學(xué)報(bào),2021,44(3):79-88.
[25] 青杰超,林子然,莫開林.金銀花和蒲公英抑菌、抗氧化以及抗紫外作用初探[J].四川林業(yè)科技,2018,39(6):55-57.
[26] 彭熙煒,閻卉芳,黃娟,等.黃芪-當(dāng)歸配伍對(duì)大鼠血管內(nèi)膜增生模型炎性反應(yīng)的影響[J].中華中醫(yī)藥雜志,2019,34(2):580-584.

相似文獻(xiàn)/References:

[1]劉江濤,萬春友,張濤,等.骨搬移術(shù)結(jié)合貫通沖洗引流治療創(chuàng)傷性骨髓炎[J].中醫(yī)正骨,2017,29(02):47.
[2]陳軼騰.胸大肌皮瓣轉(zhuǎn)位結(jié)合載抗生素人工骨移植治療鎖骨骨髓炎[J].中醫(yī)正骨,2017,29(02):60.
[3]任飛龍,郭俊,周大鵬,等.膜誘導(dǎo)技術(shù)治療成人創(chuàng)傷后骨髓炎[J].中醫(yī)正骨,2017,29(11):50.
[4]王慧彪,張海濤.負(fù)壓封閉引流聯(lián)合游離股前外側(cè)肌皮瓣移植治療脛骨遠(yuǎn)端骨髓炎合并皮膚軟組織缺損[J].中醫(yī)正骨,2018,30(02):69.
[5]劉繼權(quán),劉玙平,王玉輝,等.載抗生素硫酸鈣聯(lián)合自體髂骨植骨治療脛骨慢性骨髓炎[J].中醫(yī)正骨,2018,30(03):66.
[6]譚新歡,鄒德寶,楊慶民,等.自體富血小板血漿聯(lián)合髂骨植骨治療下肢長(zhǎng)骨慢性骨髓炎[J].中醫(yī)正骨,2018,30(11):64.
[7]劉繼權(quán),劉玙平,王玉輝,等.載抗生素硫酸鈣混合髂骨植骨聯(lián)合穿支皮瓣移植治療脛骨慢性骨髓炎[J].中醫(yī)正骨,2019,31(02):67.
[8]靳國(guó)強(qiáng),趙蕾,韓宗昌,等.感染骨段切除、短縮外固定結(jié)合載敏感抗生素硫酸鈣骨粉局部填塞治療尺橈骨骨髓炎[J].中醫(yī)正骨,2019,31(11):59.
[9]靳國(guó)強(qiáng),韓宗昌,趙蕾,等.腓骨橫向骨搬移治療脛骨骨髓炎合并大段骨缺損[J].中醫(yī)正骨,2020,32(02):64.
[10]韓杰,柴源,章曉云,等.中藥復(fù)方治療不同分期膝骨關(guān)節(jié)炎的研究進(jìn)展[J].中醫(yī)正骨,2022,34(11):57.

備注/Memo

備注/Memo:
基金項(xiàng)目:2022年云南省“興滇英才支持計(jì)劃”項(xiàng)目(云衛(wèi)人發(fā)〔2022〕8號(hào)) 通訊作者:顧海潮 E-mail:[email protected]
更新日期/Last Update: 1900-01-01